News Archives - QualityStocks

ThursdayJul 23, 2026 10:30 am

Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) Advances Precision Oncology as Biomarker-Driven Cancer Gains Momentum

Disseminated on behalf of Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) and may include paid advertising. ONC010 is being developed for biomarker-selected cancers, aligning with the growing shift toward precision medicine The company is currently advancing ONC010 through manufacturing, and IND-enabling development programs Onco-Innovations combines targeted therapeutics, nanoparticle drug delivery, and AI-native discovery to address treatment-resistant cancers Cancer treatment is undergoing one of its most significant transformations in decades. Rather than relying on the traditional “one drug fits all” approach, oncology is increasingly embracing precision medicine. This strategy uses genomic testing and biomarker analysis to identify patients most likely to benefit from specific…

ThursdayJul 23, 2026 9:45 am

SS Innovations International Inc. (NASDAQ: SSII) to Showcase SSi Mantra Surgical Robotic System at SRS 2026 as Company Expands Global Clinical Footprint

SS Innovations will showcase its SSi Mantra surgical robotic system at the Society of Robotic Surgery (“SRS”) 2026 Annual Meeting in Florida on July 23-26. The presentation will feature a live kidney telesurgery broadcast from India, demonstrating the remote capabilities of the SSi Mantra platform. Chairman and CEO Dr. Sudhir Srivastava to participate in multiple conference presentations covering telesurgery, robotic surgery adoption and regulatory developments. As of July 6, 2026, more than 12,375 procedures have been completed using the SSi Mantra system, including cardiac, pediatric and telesurgical procedures. Approximately 2,100 physicians have already been trained on the platform, which has…

ThursdayJul 23, 2026 9:00 am

SPARC AI Inc. (CSE: SPAI) (OTCQB: SPAIF) Emerges as Viable Solution to Mounting Battlefield GPS Failures

Disseminated on behalf of SPARC AI Inc. (CSE: SPAI) (OTCQB: SPAIF) and may include paid advertising. The Pentagon no longer treats jamming and spoofing as a contingency but as a baseline condition of modern conflict. Sparc AI approaches that problem from the software side rather than through new hardware, offering its Overwatch platform that delivers precision navigation and target acquisition for drones and autonomous systems. The company has also been building the commercial infrastructure to bring that technology to actual defense customers. Modern militaries-built decades of doctrine on the assumption that satellites would always know where a soldier, drone or missile stood,…

WednesdayJul 22, 2026 9:45 am

Canamera Energy Metals Corp. (CSE: EMET) (OTCQB: EMETF): Advancing Brazilian Rare Earth Assets as Global Supply Chains Look Beyond China

Disseminated on behalf of Canamera Energy Metals Corp. (CSE: EMET) (OTCQB: EMETF) and may include paid advertising. Canamera has commenced exploration at its São Sepé Project in Brazil, where three high-priority rare earth targets have already been identified The company is building a diversified Brazilian rare earth portfolio as Western nations seek alternatives to China's supply dominance These developments position Canamera to capitalize on growing demand for secure, strategic sources of critical minerals Rare earth elements have become indispensable to the technologies powering the global economy, from electric vehicles and wind turbines to advanced defense systems and consumer electronics. Yet…

WednesdayJul 22, 2026 9:00 am

VERAXA Biotech AG (NASDAQ: VRXA) Advances BiTAC(R)-TCE Development with Positive Regulatory Feedback from Germany

The company has received Scientific Advice from Germany's Paul-Ehrlich-Institute (“PEI”) supporting the proposed development strategy for its lead BiTAC(R)-TCE program. The regulatory feedback provides early guidance on the company's biological rationale, safety assessments, and non-clinical development plan, for its novel therapeutic platform. VERAXA believes the advice helps reduce development uncertainty by providing greater clarity before advancing toward clinical studies. The company's lead BiTAC(R)-TCE candidate previously generated encouraging preclinical data presented at the 2026 American Association for Cancer Research (“AACR”) Annual Meeting. VERAXA continues to build a diversified oncology pipeline that includes bispecific T-cell engagers, antibody-drug conjugates (“ADCs”) and other engineered…

TuesdayJul 21, 2026 12:40 pm

QualityStocksNewsBreaks – Greenwich LifeSciences, Inc. (NASDAQ: GLSI) Highlights Phase 3 Trial Progress and Expanded Study Design

Greenwich LifeSciences (NASDAQ: GLSI) provided an update on its Phase 3 FLAMINGO-01 trial evaluating GLSI-100, an immunotherapy designed to prevent breast cancer recurrence, announcing that the study's Data Safety Monitoring Board recommended the trial continue without modification following its May 2026 review. The company also said regulatory authorities in the U.S. and Europe have supported planned protocol changes that include expanding enrollment to as many as 2,000 patients, increasing enrollment rates by including all HLA types and maintaining enrollment through interim analyses to strengthen the study design and increase the probability of success. Greenwich LifeSciences said more than 1,500 patients…

TuesdayJul 21, 2026 11:15 am

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Developing Two-Pronged Attack on Brain Disorders Affecting Millions

Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising. Quantum BioPharma's MS focus is Lucid-MS, a patented new chemical entity that takes a fundamentally different approach from existing therapies. Supporting Lucid-MS’s phase 2 development is an ongoing imaging collaboration with Massachusetts General Hospital. The company developed unbuzzd, a proprietary dietary supplement formulated to support alcohol metabolism and reduce the acute effects of intoxication and hangover. Neurological disorders affect hundreds of millions of people worldwide, and for many of those patients, existing treatments fall far short. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM), a biopharmaceutical company, is…

TuesdayJul 21, 2026 10:30 am

American Fusion(TM) Inc. (AMFN) Secures Texas Certificate of Registration as Texatron(TM) Fusion Engine(TM) Testing Program Advances

The company has received a Texas DSHS Certificate of Registration for Industrial Radiation Machines, allowing research and development activities involving its registered Texatron(TM) Fusion Engine(TM) systems at Texas Tech University. The registration provides the principal regulatory authorization supporting the company's planned engineering, prototype testing, and validation roadmap, under applicable Texas radiation control regulations. The certificate covers 12 Texatron(TM) Fusion Engine(TM) research systems, ranging from 500 kW to 1 GW, reflecting the breadth of the company's planned development platform. The milestone follows months of regulatory review and supports the next phase of the company's technical development program, including calibration, diagnostics and…

TuesdayJul 21, 2026 9:45 am

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Hits Key Study Milestone as Early MS Imaging Data Shows Promising Signal

Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising. Multiple sclerosis is one of the most common neurological diseases affecting young adults worldwide. Study is evaluating technique that allows researchers to tell the difference between nerve damage that may still be reversible and damage that is permanent. Quantum BioPharma reports two key developments: patient enrollment in the pilot study has reached its halfway mark and preliminary imaging data is encouraging. A key imaging study examining a novel approach to tracking multiple sclerosis (“MS”) has reached its halfway point in patient enrollment, with early results…

TuesdayJul 21, 2026 9:00 am

BOXABL Inc. (NASDAQ: BXBL) Is ‘One to Watch’

BOXABL is advancing a factory-based approach to housing that seeks to standardize production and improve cost efficiency in a traditionally fragmented industry. The company is targeting a large addressable market supported by a significant housing supply gap and long-term affordability challenges. Its modular system is designed to scale across multiple use cases, from individual homes to large residential and commercial developments. The company is embedding automation and AI into factory operations to improve throughput, reduce defects, and optimize production efficiency. BOXABL’s model pairs lower-margin home production with higher-margin service opportunities such as financing, insurance, and maintenance. BOXABL (NASDAQ: BXBL) is a…

Site Search

Company Search

Category: News